FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Amarin Corporation plc Stock AnalysisComprehensive stock analysis for Amarin Corporation plc (AMRN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAMRN
AMRN
Amarin Corporation plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
AMRN
Home🔹Stocks🔹Amarin Corporation plc

Amarin Corporation plc

AMRN•NASDAQ

Amarin Corporation plc

AMRN•NASDAQ
Market cap
$288.52M
Sentiment

Your view on AMRN

Mkt Cap
$288.52M
Sentiment
Your view
AMRN
Amarin Corporation plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
AMRN
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Amarin Corporation plc

Industry
Biotechnology
Sector
Healthcare
CEO
Aaron D. Berg
Headquarters
Grand Canal Docklands, Dublin, IE
Industry
Biotechnology
Sector
Healthcare
CEO
Aaron D. Berg
Headquarters
Grand Canal Docklands, Dublin, IE
Description

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News